Skip to main content

Advertisement

Fig. 1 | Respiratory Research

Fig. 1

From: Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis

Fig. 1

Effect of ex vivo treatment with Pirfenidone and Nintedanib on the fibrotic phenotype of 3D-LTCs. a Representative immunofluorescence analysis of Collagen I, α-SMA and E-Cadherin in control (PBS) and fibrotic (Bleo) 3D-LTCs after 48 h in culture. Scale bar represents 50 μm. b Gene expression analysis by qPCR of fibrotic marker Fn1 and Col1a1 in control and fibrotic 3D-LTCs after 48 h in culture. ΔCp relative to Hprt is presented as mean ± SEM, n = 7. Means were compared using Wilcoxon matched pairs test. c Collagen I secretion of control and fibrotic 3D-LTCs was determined by WB and normalized to supernatant volume. n = 6. Means were compared using Mann-Whitney test. d WISP1 secretion of control and fibrotic 3D-LTCs was measured by ELISA. n = 7. Significance was assessed using Wilcoxon matched pairs test. e, f Fibrotic 3D-LTCs were cultured for 48 h in the presence of anti-fibrotic drugs (e) Nintedanib (0.1 μM, 1 μM, 10 μM) (f) and Pirfenidone (100 μM, 500 μM, 2.5 mM). Gene expression analysis by qPCR of fibrotic marker Fn1 and Col1a1. Log fold change is presented as mean ± SEM, n = 5–7. Means were compared to respective DMSO control using one-sample t-tests in comparison to a hypothetical value of 0. g Collagen I secretion of fibrotic 3D-LTCs treated with Nintedanib (1 μM) and Pirfenidone (500 μM) for 48 h was determined by WB and normalized to supernatant volume. n = 5. Significance was assessed using Wilcoxon matched pairs test. Significance: *p < 0.05, **p < 0.01

Back to article page